ID: ALA1096359

Max Phase: Preclinical

Molecular Formula: C16H20N2O3S

Molecular Weight: 320.41

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C([C@@H]1CCCN1C(=O)OCc1ccccc1)N1CCSC1

Standard InChI:  InChI=1S/C16H20N2O3S/c19-15(17-9-10-22-12-17)14-7-4-8-18(14)16(20)21-11-13-5-2-1-3-6-13/h1-3,5-6,14H,4,7-12H2/t14-/m0/s1

Standard InChI Key:  UJBOEHNGHKEEQC-AWEZNQCLSA-N

Associated Targets(non-human)

PREP Prolyl endopeptidase (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 320.41Molecular Weight (Monoisotopic): 320.1195AlogP: 2.32#Rotatable Bonds: 3
Polar Surface Area: 49.85Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 1.76CX LogD: 1.76
Aromatic Rings: 1Heavy Atoms: 22QED Weighted: 0.86Np Likeness Score: -1.23

References

1. Lawandi J, Gerber-Lemaire S, Juillerat-Jeanneret L, Moitessier N..  (2010)  Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors.,  53  (9): [PMID:20058865] [10.1021/jm901104g]

Source